Navigation Links
Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Date:10/16/2007

NATICK, Mass., Oct. 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from October 20 to 25 in Washington, D.C.

Boston Scientific will be announcing a wide range of safety and efficacy data on its market-leading TAXUS(R) Express2(TM) and TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent Systems, including final five-year results from the TAXUS IV clinical trial, which studies the TAXUS Express(TM) Stent, and nine- month data on small vessels and long lesions from the ATLAS trial, which studies the TAXUS Liberte Stent. In addition, the Company will present long- term data from the TAXUS V de novo clinical trial and the TAXUS ARRIVE registry.

"The extensive data to be presented at TCT will continue to reinforce the safety, efficacy and deliverability of the TAXUS Stent Systems," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "We are pleased to be able to complement our market-leading TAXUS Stents with the addition of our PROMUS(TM) Everolimus Eluting Coronary Stent System in international markets, and the industry's deepest drug-eluting stent (DES) pipeline, which includes our third-generation TAXUS(R) Element(TM) Stent -- currently in clinical trials."

PROMUS is a private-labeled XIENCE(TM) V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific Corporation outside the United States. It is currently pending approval by the U.S. Food and Drug Administration and is not commercially available in
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Inspire Announces Presentations at Two European Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on Form ... by Mallinckrodt plc on May 16, 2014 and amended on ... Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, ... on Form S-4 is available on the SEC,s EDGAR system, ...
(Date:7/14/2014)... -- BioAdaptives, Inc. (OTCBB:BDPT) is pleased to announce Mr. ... of President and CEO of the Company.  Mr. Epling ... that licensed its formulation, intellectual properties, and other technologies ... "Mr. Gerald Epling , who has been ... held entity to a public company, has decided to ...
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7BioAdaptives Prepares for Next Step 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3
(Date:7/14/2014)... pathologist Lukas Kenner and his colleagues have developed a ... tissue sections and demonstrate the presence of specific biomarkers ... of the disease and leads to the most suitable ... study, "Two independent pathologists concur with each other only ... developed software offers, for the first time, the option ...
(Date:7/14/2014)... July 14, 2014 Last month Bromell ... their website. The webpage features more detailed information on ... including motorcycles, RVs, ATVs, and boats in the state ... this new feature to the website in order to ... helps encompass the purpose of the website, which is ...
(Date:7/14/2014)... is he who "begins to age". But laboratory biology ... not a synonym of ageing, it is also not ... a badly named physiological process that those who do ... That is the case of Manuel Serrano, from the ... world,s leading experts on senescence, who has just published ...
(Date:7/14/2014)... may buffer some of the adverse health effects of ... researchers from the American Cancer Society, The Cooper Institute, ... the journal Mayo Clinic Proceeding s, and finds ... blood markers associated with cardiovascular disease is markedly less ... has been linked to an increase risk of obesity, ...
(Date:7/14/2014)... Botanica Day Spa announced last month that their ... the day spa in down town Clearwater, FL on ... refreshments will be served as clients are invited to ... and great deals on spa services, including the ... (also known as “facial shaving”) is a simple and ...
Breaking Medicine News(10 mins):Health News:Scientists developed new technology for the diagnosis of cancer cells 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3
... mortality for hospitalized patients, study found , , TUESDAY, Oct. ... hospitalized for pneumonia was one-third lower for those taking ... a Danish study found. , While the findings are ... doctors can prescribe statins as infection fighters, experts said. ...
... Intentional Interference with ... Prospective Business Advantage, CAMBRIDGE, Mass., Oct. ... it had filed an action for injunctive,relief and damages against ... Hemopure, hemoglobin glutamer-250,(bovine), Biopure,s oxygen therapeutic product for human use. ...
... ... Cost Reduction Efforts Continue to Generate Results ... Step for Visian Toric ICL Application to ... FDA, MONROVIA, Calif., Oct. 28 STAAR ...
... disease rises as the joint ailment worsens, research shows ... (RA) may increase the risk of gum disease, a ... link between RA and periodontal disease, a condition where ... from the gums, loss of bony support, and possible ...
... 28 Blue Mountain Quality,Resources, Inc. announced ... Regulatory Asset Manager(R) to satisfy their immediate ... their enterprise-wide,SAP(R) implementation., "Alexion is committed ... in,its manufacturing facilities and other operations," explains ...
... 28 NASA satellite data can,improve forecasts of ... that can,benefit public health managers. Scientists announced the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ), Led by ... Mexico in,Albuquerque, and William Sprigg of the University ...
Cached Medicine News:Health News:Statins Reduced Death Risk From Pneumonia 2Health News:Statins Reduced Death Risk From Pneumonia 3Health News:Biopure Sues National Institutes of Health Official 2Health News:Biopure Sues National Institutes of Health Official 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 2Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 3Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 4Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 5Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 6Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 7Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 8Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 9Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 10Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 11Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 12Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 13Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 14Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 15Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 16Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 17Health News:STAAR Surgical Reports 33% Third Quarter Revenue Growth 18Health News:Rheumatoid Arthritis May Harm Gums 2Health News:Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R) 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 2Health News:NASA-Enhanced Dust Storm Predictions to Aid Health Community 3
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: